
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen Inc has demonstrated strong financial performance, with a significant 19% year-over-year revenue growth and a notable increase in average selling prices (ASPs) of 9% year-over-year, currently sitting at $441 per test. The company's strategic expansion into additional sales territories, projected to reach 45 by the end of 2025, alongside improvements in commercial leadership, positions it well for continued volume growth. Furthermore, with Q3 revenue increasing by 38% year-over-year and ongoing advancements in reimbursement strategies to support further price increases, Exagen is on track to achieve its long-term ASP target, enhancing a positive outlook for its stock.
Bears say
Exagen Inc's financial outlook appears negative due to a significantly lowered growth projection for 2026, coupled with delayed expectations for positive free cash flow and a decline in peer multiples. These factors have prompted adjustments to the company’s revenue estimates and expectations of more muted gross margin expansion, contributing to a decrease in price targets. Additionally, a notable drop of over 60% in share value following the 3Q25 results has raised concerns among investors regarding the loss of a direct billing account, which accounted for 2% of volume, thereby adversely impacting growth and profitability timelines.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares